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ABSTRACTS
Introduction of approach
VP Werth Departments of Dermatology, Philadelphia Veterans’ Affairs Medical
Center and University of Pennsylvania, Philadelphia, USA
This is just the third time our international community has formally met. We are
consequently a very young field and there are important questions that need to be
addressed as a group. One goal of the current meeting is to begin to develop (1)
definitions related to CLE, (2) diagnostic criteria for CLE that allow diagnosis of a
specific type of CLE or lupus-associated skin lesion, and (3) subsequently begin the
process of evaluating and developing a classification for CLE and that incorporates
the most recent scientific developments in the field. This is important so that we
communicate with the same terminology within our field, as well as with other
specialities that evaluate and care for patients with lupus. Clear definitions and
criteria related to CLE will facilitate clinical and research studies in the field. In
rheumatology, OMERACT has utilized the Delphi technique to allow input from the
diverse members of a scientific community to have an equal voice in determining
the components that can be then voted on iteratively, with the final goal to develop
a product (diagnostic and classification criteria) that can be further tested in live
patients, then further refined. This is a model that could be applied to other areas of
autoimmune skin disease, including dermatomyositis, vasculitis, and morphea/
scleroderma. It is thus important to give careful consideration of the methodology
for beginning this approach.
LUPUS BASIC SCIENCE
Hydroxychloroquine reduces the lupus erythematosus-like skin lesions in
MRL/lpr mice
T Shimomatsu12, H Li1, T Ikeda1, N Kanazawa1, F Furukawa1 1 Department of
Dermatology, Wakayama Medical University and 2 Department of Dermatology,
Wakayama Rosai Hospital, Wakayama, Japan
Hydroxychloroquine (HCQ) is an antimalarial drug which has been used to treat
inflammatory disorders, including arthropathy of rheumatoid arthritis, arthropathy
and cutaneous symptoms of systemic lupus erythematosus (SLE), and cutaneous LE
(CLE). As underlying mechanisms for these clinical effects of HCQ, it has been
shown that HCQ can suppress the production of prostaglandins and inflammatory
cytokines and regulate the innate immune system. However, the precise
mechanisms by which HCQ exerts its effect on CLE, especially in vivo, are still
undefined. Therefore, in this study, we administered HCQ to MRL/lpr mice, well-
known model mice for SLE that occasionally present LE-like skin lesions, for 4
months since 3 months of age, and examined its safety and effect on LE-like lesions.
As a result, 6 among 13 mice in the group given drinking water, 3 among 11 mice
in the group administered low-dose HCQ (4mg/kg/day), and 2 among 11 mice in
the group administered high-dose HCQ (40mg/kg/day) presented the skin lesions.
Mortality rate was 24% in the group of water, 8% in the group of low-dose HCQ
(4mg/kg/day), and 8% in the group of high-dose HCQ (40mg/kg/day). Mean body
weight gain was 4.6, 8, and 5.1 g, respectively. These results suggested that HCQ
had therapeutic effects on LE-like skin lesions without adverse effects.
Skin-antigen specific antibodies are detected in UV irradiation and TLR7 agonist
induced lupus-like disease in autoimmune prone NOD mice and in pediatric SLE
M Ghoreishi1, L Tucker2, and JP Dutz1 1 Department of Dermatology & Skin
Science and 2 Department of Pediatrics, University of British Columbia,
Vancouver, Canada
Purpose: The role of environmental precipitants in systemic lupus erythematosus
(SLE) remains unclear. We wished to determine whether UV þ /- TLR7 activation
would induce lupus-like disease in an autoimmune mouse model and assess
relevance in humans. Methods: Female NOD (non obese diabetic) mice received
weekly UVB radiation or 25 ug of topical imiquimod or both. Serum was collected
for detection of anti-nuclear antibodies (ANA), desmoglein 3 (Dsg3) antibodies,
IFNa by ELISA and pro-inflammatory cytokines. Blood was collected for flow
cytometry. Dsg-3 antibodies were measured in the serum of children with SLE, type
1 diabetes (T1D) and controls. Results: Imiquimod treatment enhanced UV-induced
ANA and Dsg3 antibody production in NOD mice. Systemic immune activation
was detected as evidenced by serum IL-6, TNFa, IFNg, MCP-1. Serum IFNa was
elevated following combination therapy. Combination therapy up-regulated TLR-7
and IFNa expression in the peripheral blood PDCs. Anti-Dsg-3 antibodies were
detected more frequently in children with SLE (5/19) than in children with T1D (1/9)
or controls (0/10). Conclusions: These studies demonstrate that UV light combined
with TLR7 engagement induces SLE-like disease in autoimmune prone animals. The
presence of anti-Dsg3 antibodies in a pediatric SLE suggests that skin-specific
autoimmunity occurs in a subset of patients with SLE.
TREX1 in Familial Chilblain Lupus
MA Lee-Kirsch Department of Pediatrics, University Hospital, Technical University
Dresden, Dresden, Germany
The elucidation of the genetic cause of the rare monogenic form of cutaneous
lupus, familial chilblain lupus, has provided novel insights into cell-intrinsic
mechanisms leading to autoimmunity. Autosomal-dominant familial chilblain
lupus is characterized by cold-induced inflammatory lesions at acral locations that
manifest within the first years of life. Familial chilblain lupus is caused by mutations
in TREX1 encoding a cytosolic DNA exonuclease with specificity for single-
stranded DNA. In addition, rare TREX1 variants confer a high risk for systemic lupus
erythematosus. It is thought that accrual of intracellular nucleic acid species due to
TREX1 deficiency leads to activation of the innate immune system mediated by
type-I-interferon, a hallmark of lupus pathogenesis. Here, I will summarize our
current knowledge on the pathogenesis of TREX1-associated forms of lupus
erythematosus.
LUPUS CLINICAL
Subtypes of lupus in Asia
F Furukawa Department of Dermatology, Wakayama Medical University,
Wakayama, Japan
Genome-wide association study (GWAS) of systemic lupus erythematosus in Asian
population allowed us for a direct comparison with that in European population.
There are several differences between Asia and Europe from studies of Chinese Han
population, Japanese population and others. At present, we have no direct
evidences that these variations are associated with skin manifestation difference in
incidence and/or clinical features. However, it is a key issue to study race
characteristics of cutaneous lupus manifestation for understanding of better
treatment and QOL. Race differences were discussed on subacute cutaneous
lupus erythematosus (SLCE), neonatal LE and drug-induced LE. SCLE: In Caucasian,
SCLE is thought to be a clinical subset of LE. However, LE patients with pure
annular SCLE and/or with pure papulosquamous SCLE lesions are rare in Japanese.
Most patients with pure annular SCLE have atypical annular erythema with other
types of LE-specific skin lesions. And also there are many transitional cases between
annular SCLE and Sjo¨gren’s annular erythema. Sjo¨gren’s annular erythema is more
common in Oriental than Caucasian. Neonatal LE:
Neonatal LE is thought to be SCLE of infant in general. In Japan the mothers of
neonatal LE patients are usually diagnosed as Sjo¨gren’s syndrome and the annular
erythema in neonatal LE is closely related with Sjo¨gren’s annular erythema. It is
important among Asian dermatologists to understand the similarity or difference
between the annular SCLE and Sjo¨gren’s annular erythema from genetic
background.
Epidemiology of CLE: incidence, prevalence, medications, cancer
F Nyberg Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden
Lupus erythematosus (LE) is a disease that includes a broad spectrum of symptoms,
from localized cutaneous LE (CLE) to severe systemic LE (SLE). CLE is a chronic,
inflammatory skin disease with a wide range of manifestations that can be seen in
patients with or without SLE. Based on histopathological changes, the skin
manifestations of LE can be divided into LE-specific (¼CLE) and LE-non-specific
manifestations. Due to different classifications and considerable overlap issues, the
incidence and prevalence of CLE has until recently been based on estimations and
population-based data have not been available. We have studied the epidemiology
of CLE in Sweden based on registers, including different comorbidities, risk for
progression to SLE, risk for cancer among CLE patients and the association between
drug exposure and the development of subacute CLE. An overview of recent
publications in the field will be given. Population-based registry data on CLE
epidemiology will potentially be useful in the care of CLE patients, planning of
health care as well as clinical trials. For prospective studies, especially of the
intermediate group between CLE and SLE, quality registers based on internationally
accepted uniform criteria, will be needed to further improve the health care for CLE
patients.
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ABSTRACTS
Quality of Life in Lupus and Dermatomyositis
SM Verma, VP Werth1 Departments of Dermatology, Veterans’ Affairs Medical
Center and University of Pennsylvania, Philadelphia, USA
Cutaneous lupus (CLE) and dermatomyositis (DM) are both associated with a poor
quality of life (QOL). The development of a validated disease specific scoring tool
in CLE, the Cutaneous Lupus Area Activity and Severity Index (CLASI), and in DM,
the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), have
enabled the prospective collection of data in each disease process and the
assessment of disease impact on QOL. CLE related disease activity, as measured by
the CLASI, and not disease damage or the distribution of damage, has been shown
to have a significant impact on QOL. Improvement in CLE related disease activity,
also significantly correlates with improvement in QOL, as measured by the
Skindex. Specific parameters in CLE, including lupus related alopecia, disease
activity with facial involvement, and photosensitivity also have a negative impact
on QOL. Racial variation does exist in CLE related disease activity and damage,
with an earlier onset of disease damage in African Americans than in Caucasians,
and often occurring in conjunction with disease activity. Patients with DM have a
poor QOL that is comparably worse than other dermatological and non-
dermatological diseases. In dermatomyositis, disease activity, as measured by the
CDASI, also has a significant impact on QOL, as measured by the Skindex.
Cutaneous symptoms of pruritus, experienced as part of DM, also have a significant
impact on quality of life. In both DM and CLE, patients demonstrate poor mental
health.
Current Categorizations of Cutaneous Lupus Erythematosus and Lupus Non-
Specific Skin Lesions
M Costner
In the American College of Rheumatology’s 2006 position paper ‘‘Development of
Classification and Response Criteria for Rheumatic Diseases’’, the authors note that
rheumatic diseases are characterized by overlapping features, lack of a
pathognomonic diagnostic test, and widespread manifestations which hinders
diagnosis and presents a tremendous challenge when conducting and evaluating
the results from clinical research. This observation certainly applies to cutaneous
lupus erythematosus (CLE). Rheumatologic dermatologists have attempted to find
solutions to this quandary for the last several decades with the development of
several classification schemes. Each of these has distinct advantages and
disadvantages. The Gilliam Classification (1977), parts of which continue to be
the basis for many of the currently proposed classifications, emphasized that LE skin
lesions exist along a continuum, stressing the value of sub-classification of
cutaneous LE on the basis of shared clinical, pathologic and laboratory features,
and assigned the terms acute, subacute, and chronic. Kuhn et al addressed the
dilemma of where to classify tumid lupus (LET), and proposed a fourth subtype of LE
called intermittent cutaneous lupus erythematosus (ICLE) as part of the 2003
Dusseldorf Classification of Cutaneous Lupus Erythematosus. Lipsker (2010) Lee
(1998), and Sontheimer, (unpublished manuscript) have suggested sub-classifica-
tion of lupus-specific skin disease based on the predominant location of the
inflammatory infiltrate. It is important to critically evaluate each classification
approach so that consensus may be reached regarding the development of an ideal
set of criteria.
Derivation and validation of the Systemic Lupus International Collaborating
Clinics (SLICC) classification criteria for SLE
A Zoma FRCP
The Systemic Lupus International Collaborating Clinics (SLICC) group revised the
American College of Rheumatology (ACR) SLE classification criteria in order to
improve clinical relevance, meet stringent methodology requirements and
incorporate new knowledge regarding the immunology of SLE. The SLICC criteria
were derived from a set of 702 expert-rated patient scenarios. Recursive
partitioning was used to derive an initial rule based on SLICC physician consensus.
The SLICC group validated the criteria in a new sample of 690 new expert-rated
patient scenarios. Seventeen criteria were identified. In the derivation set, the
SLICC criteria resulted in fewer misclassifications compared with the current ACR
criteria (49 versus 70; P¼0.0082) and had greater sensitivity (94 vs 86%;
Po0.0001) and equal specificity (92 vs 93%; P¼0.39). In the validation set, the
SLICC criteria resulted in fewer misclassifications compared with the current ACR
classification criteria (62 vs 74; P¼0.24) and had greater sensitivity (97 vs 83%;
Po0.0001) but lower specificity (84 vs 96%; Po0.0001). In conclusion, the new
SLICC criteria performed well in a set of patient scenarios rated by experts.
According to the SLICC rule for the classification of SLE, the patient must satisfy at
least 4 criteria, including at least one clinical criterion and one immunologic
criterion OR the patient must have biopsy-proven lupus nephritis in the presence of
antinuclear antibodies or anti-double-stranded DNA antibodies.
Current practice variations in cutaneous lupus therapy and thoughts about
international guidelines
JC Szepietowski1, V Werth2, F Furukawa3, D Samotij1, A Reich1 1 Department of
Dermatology, Venereology and Allergology, Wrocław Medical University,
Wroclaw, Poland 2 Departments of Dermatology, Philadelphia Veterans’ Affairs
Medical Center and University of Pennsylvania, Philadelphia, Pennsylvania, and
3 Department of Dermatology, Wakayama Medical University, Wakayama, Japan
A questionnaire about various aspects of CLE treatment recommendations was
distributed to Japanese, American, and European CLE experts. 51 completed
questionnaires were assessed in the preliminary analysis. Majority of participants
(84%) were university workers. Sunscreens use was recommend by almost all
physicians, as well as use of other sun-protective measures. Ultra-potent and potent
corticosteroids as well as calcineurin inhibitors were the most often recommended
topical therapy for all CLE subtypes. Involvement of internal organs (71%), CLE
severity (71%) and response to topical therapy (51%) were the most important
factors influencing the decision of systemic treatment. Systemic therapy was most
commonly introduced immediately in acute CLE, after failure of one topical therapy
in intermittent/tumid CLE and after failure of two topical therapies in subacute and
chronic CLE. Corticosteroids, antimalarials, cyclosporine A, tacrolimus, and
mycophenolate mofetil were considered as the most suitable and effective systemic
drugs for CLE patients. Physician global assessment was most often used to assess
treatment efficacy (71%). Physicians usually waited one (43%) or two months
(33%) to modify the treatment if not effective. Great variability of achieved answers
underlines the need of development of CLE treatment guidelines.
Diagnostic versus classification criteria for cutaneous lupus erythematosus
MK Connolly, MD Departments of Dermatology and Medicine, University of San
Francisco, San Francisco, USA
There is considerable confusion over the terminology describing CLE. Varying
nomenclature leads to uncertainty regarding which patients are being studied and
impairs our ability to communicate. The ACR uses ‘‘diagnostic criteria’’ to diagnose
individual SLE, but not CLE, patients whereas ‘‘classification criteria’’ are meant to
identify a group of patients with a specific diagnosis that can be used in research
studies. For CLE, individual authors define which patients they are studying in each
paper and this differs between authors. Classification criteria for CLE often refers to
LE-nonspecific (over 20 items in this category) and LE-specific lesions (14 items in
this category). The LE-specific groups were further divided into: acute (ACLE),
subacute (SCLE) and chronic (CCLE). These are the ‘‘Gilliam Classification’’,
originally published in 1977. Over the years these have been accepted with the
understanding that they are not perfect. Criticisms include that chronicity is
imprecise (i.e. some SCLE patients can have chronic lesions); and they do not
incorporate either dermatopathology or pathogenesis data adequately. Modifica-
tions to the Gilliam classification have been proposed: Dusseldorf criteria 2003;
Lipsker criteria 2010; and the Gilliam-Sontheimer criteria 2013. Each of these
systems has something to offer, but none have been universally accepted. There is a
need to have consensus-derived diagnostic and classification criteria for CLE
incorporating existing definitions and new ideas that are accepted by the
international community seeing and studying CLE.
Duesseldorf Classification of Cutaneous Lupus Erythematosus
A Kuhn Department of Dermatology, University of Muenster, Muenster, Germany
Lupus erythematosus (LE) is a chronic inflammatory autoimmune disease with a
heterogeneous clinical presentation. In contrast to the multi-organ disease systemic
LE (SLE), patients with cutaneous LE (CLE) present with manifestations primarily
confined to the skin. However, the development of a unified classification of skin
manifestations has proven difficult. The classification system developed by Gilliam
in 1977 divided cutaneous lesions into LE-specific and LE-nonspecific manifesta-
tions. Skin lesions such as urticarial vasculitis and livedo reticularis are some of the
most common LE-nonspecific cutaneous lesions and are primarily associated with
active SLE, reflecting potentially serious complications. The LE-specific cutaneous
findings encompass the various subtypes of CLE: acute CLE (ACLE), subacute CLE
(SCLE), and chronic CLE (CCLE), including discoid LE (DLE), Chilblain LE (CHLE),
and LE panniculitis (LEP). Since the initial description of Gilliam’s nomenclature
more than three decades ago, several attempts have been made to improve this
classification system. An additional subtype with characteristic clinical, histologi-
cal, and photobiological features, termed LE tumidus (LET), was first described in
1909, and has 2004 been defined as a separate entity of CLE. In particular,
phototesting has been crucial in confirming LET as a separate entity of the disease
spectrum. Due to its benign, intermittent course, a modified classification system,
the ‘‘Duesseldorf Classification’’, has been proposed, including LET as the
intermittent subtype of CLE (ICLE).
www.jidonline.org 1485
ABSTRACTS
Update of EUSCLE including the Core Set Questionnaire
A Kuhn Department of Dermatology, University of Muenster, Muenster, Germany
The ‘‘European Society of Cutaneous Lupus Erythematosus’’ (EUSCLE) has the
primary task to achieve consensus concerning evidence-based clinical standards
for disease assessment and therapeutic strategies in patients with cutaneous lupus
erythematosus (CLE). In 2009, a study group of EUSCLE defined a core set of
variables to facilitate standardized data collection in different subtypes of the
disease, resulting in the EUSCLE Core Set Questionnaire. In a recent study, data of
1002 patients with CLE from 14 countries were collected and different clinical,
diagnostic, and therapeutic parameters were analyzed. In 34.6% of the 1002
patients, two or more CLE subtypes were diagnosed during the course of the disease
and 45.2% presented also with LE-nonspecific manifestations. Sunscreens were
applied by 84.0% of the study cohort and showed a high efficacy in preventing skin
lesions in all disease subtypes. Topical steroids were used in 81.5% of the CLE
patients, with an efficacy of 88.4%, whereas calcineurin inhibitors were applied in
16.4% of the study population and showed an efficacy of 61.7%. Furthermore,
antimalarial agents, such as hydroxychloroquine, were confirmed to be the first-
line systemic treatment for all disease subtypes. In summary, the EUSCLE Core Set
Questionnaire provides a useful tool for standardized collection of data on CLE in
clinical practice. It enables consistent exchange and comparison of patient’s data
within several European countries and will contribute to standardized assessment
and monitoring of the disease in Europe.
Treatment of cutaneous lupus
S Jessop University of Cape Town and Groote Schuur Hospital, Cape Town, South
Africa
Lupus erythematosus presents in a wide variety of ways, the most distinctive forms
being acute systemic lupus, (ACLE), subacute cutaneous lupus, (SCLE), and chronic
discoid lupus, (DLE). Early literature focused on the use of oral agents such as
antimalarials, dapsone, clofazimine and gold, topical steroids and sun protection.
Treatment choices were largely based on case reports and expert opinion. The most
robust recent evidence for efficacy comes from trials involving people with DLE.
Unfortunately, some of these studies have been marred by poor design and unclear
outcome measures. Controlled trials provide some support for the use of
antimalarials, clofazimine, sunscreens and topical steroids and tacrolimus. Trials
performed in people with SLE suggest that methotrexate and antimalarials may be
beneficial for some of the skin lesions in patients with systemic disease, although
clear details were not supplied. There is evidence to support the use of sunscreens
in the prevention of cutaneous lupus.
Dapsone and retinoids
E Aberer, M Klebes, N Wutte Department of Dermatology, Medical University of
Graz, Austria
Lupus erythematosus (LE) is a complex autoimmune disease involving the skin and
several organs. Immunomodulators such as dapsone or retinoids were proved to be
effective in some cutaneous LE (CLE) subtypes. In a retrospective study, we
analyzed 34 patients with different lupus types (7 male, 27 female; mean age 49
years ± SD 16) who were treated with dapsone monotherapy or combined with
antimalarials (AM) for a mean of 18 (range 1 – 82) months at a median dose of
100mg/d. Healing of the cutaneous lesions was recorded in 6 (17.6%), an
improvement in 14 (41.2%) and a constant course in 6 (17.6%) patients. Dapsone
was discontinued in 8 (23.5%) cases, in 4 of these patients due to side effects. There
was no difference in the outcome between dapsone monotherapy and combination
therapy with AM. These data were similar to a recent study with improvement in
30/55 (55%) CLE patients. In a double-blinded randomized controlled trial
comparing acitretin to hydroxychloroquine, about half of patients demonstrated
subjective improvement with acitretin. Similarly, isotretinoin has also been used
successfully in treating discoid LE and SCLE and also hypertrophic LE, as reported in
multiple case reports and open studies also in combination with AM. Recently
alitretinoin was administered in 3 patients with good efficacy. Dapsone and
retinoids can be used as alternatives in patients with recalcitrant CLE. Their use
must be evaluated based on individual risk-benefit concerns.
New clinical treatments in CLE
VP Werth Departments of Dermatology, Philadelphia Veterans’ Affairs Medical
Center and University of Pennsylvania
Approximately 10% of patients with CLE activity are refractory to all standard
treatments. These refractory patients frequently have severe disease and thus lack of
therapy has a profound effect on their quality of life. When patients do respond to
treatment, as with mycophenolate mofetil or methotrexate, their QoL improves.
There has been the clinical impression that adding quinacrine to hydroxychlor-
oquine (HCQ) can be beneficial, and a recent small prospective cohort studies
suggest improvement in 66% of patients with this combination who did not respond
to HCQ alone. A number of SLE randomized controlled studies that have evaluated
the skin. Abetacept (CTLA4Ig), a medication that selectively modulates the CD80/
CD86:CD28 costimulatory signal had no effect on the skin, using a pre-specified
flare endpoint. Belimumab (Anti-BLyS) is a monoclonal antibody that prevents
maturation of B lymphocytes. There was a significant reduction in the SELENA
SLEDAI score, leading to FDA approval of the drug for SLE. A post-hoc analysis
indicates improvement in the mucocutaneous lesions in the SLE patients studied,
but the efficacy rate and time to improvement will require additional study.
Additional case reports and open-label studies suggest individual patients improved
with Tocilizumab (anti-IL-6), Ustekinumab, Alitretinoin, Rituximab, polypodium
leucotomas, and Apremilast (PDE4 inhibitor). With a validated disease severity
measure and many potentially effective new approaches to treatment, it is hoped
that future multicenter trials will improve the understanding about the biology and
efficacy of these new approaches.
Systemic involvement in cutaneous lupus patients
B Chong Department of Dermatology, University of Texas Southwestern Medical
Center, Dallas, USA
Diagnosing systemic lupus erythematosus (SLE) in cutaneous lupus erythematosus
(CLE) patients has implications for prognosis and treatment. The eleven American
College of Rheumatology SLE criteria have been widely used by practitioners to
diagnose SLE. Criticisms of these criteria include that they do not differentiate other
skin diseases, and that they are heavily weighted towards cutaneous manifestations.
The Systemic Lupus International Collaborating Clinics (SLICC) group recently
recommended new SLE diagnostic criteria to address these specific limitations,
amongst others. Recent epidemiological studies in Minnesota and Sweden have
noted that close to 20% of CLE patients may develop SLE. The longer the patient
carries the diagnosis of CLE, the lower one’s risk has for progression to SLE. Various
clinical and laboratory indicators, such as widespread discoid lesions, arthralgias/
arthritis, nail changes, anemia, leukopenia, high erythrocyte sedimentation rates
(ESRs), and high titers of anti-nuclear antibodies (ANAs), have been identified as
risk factors for SLE development. To assess the risk of SLE development in CLE
patients, complete skin exams, joint assessments, and laboratory tests including
ANA, ESR, and complete blood counts should be performed regularly. Prospective
studies following CLE patients who do or do not develop SLE are currently
underway through the Cutaneous Lupus Registry at University of Texas South-
western Medical Center. We are seeking to identify clinical features and biomarkers
that improve our assessment of risk of systemic spread in these patients.
Antimicrobial peptides in cutaneous lupus erythematosus
R Gla¨ser1, T Gambichler2 and A Kreuter2 1 Department of Dermatology, University
Hospital of Schleswig-Holstein, Kiel, Germany and 2 Department of Dermatology,
Venereology, and Allergology, Ruhr-University, Bochum, Germany
Antimicrobial peptides and proteins (AMP) are small effector molecules of the
innate immune system. Apart from their potent antimicrobial activity recent studies
show that some AMP have also immunoregulatory functions and may play a role in
the pathogenesis of inflammatory diseases. In patients with cutaneous lupus
erythematosus (CLE) skin infections occur only rarely. Aim of our study was to
determine the expression of different classes of AMP in various subtypes of CLE.
Lesional skin samples were obtained from patients with discoid LE (DLE), subacute
CLE (SCLE) and lupus erythematosus tumidus (LET). In addition, tissue samples from
patients with psoriasis and healthy controls were evaluated. Skin lesions were
analyzed for the gene and protein expression of human b-defensins (hBD) -1, -2,
and -3, RNase-7, LL-37, and psoriasin (S100A7) using RT-PCR and immunohis-
tochemistry. hBD-2, -3, LL-37, and psoriasin were significantly higher expressed in
CLE as compared to healthy controls. Most AMP were significantly higher induced
in SCLE as compared to DLE and LET. SCLE and DLE showed a similar correlation of
AMP gene expression. Gene expression of AMP paralleled well with the
immunoreactivity. The low prevalence of skin infections in CLE could be explained
by the induction of different AMP shown in our study. If AMP additionally may play
a pathogenic role in CLE will be discussed.
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B-cell targeted therapies for cutaneous manifestations of systemic lupus
erythematosus: responses depend on pattern of skin involvement
EM Vital, M Wittmann, S Edward, M Goodfield, P Emery NIHR Leeds
Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust,
Leeds, UK
Background: Rituximab is widely used for SLE. Cutaneous disease in SLE is
heterogeneous and the roles of B cells are not entirely clear. We previously
reported that cutaneous response to rituximab was less consistent than in other
systems[1]. Patients: We present a detailed assessment of 16 patients with
cutaneous disease who received 2x1000mg rituximab. Results: We observed four
patterns of response: 1. Non-response in CDLE: 4 patients showed no significant
improvement; 2. Good response in cutaneous vasculitis: In 2 patients, skin
involvement resolved completely. 3. Good response in ACLE or SCLE (with or
without switch to different lupus-like cutaneous disease): Most patients with
subacute or acute photoaggravated LE initially responded, but 4 patients later
developed localized or disseminated discoid LE. Additionally, 2 patients with SLE
but no skin involvement at baseline developed SCLE shortly after rituximab. 4.
Developing non-CLE skin disease: a 30-year-old woman developed pemphigus
vulgaris, and another developed psoriasis. Conclusions: These findings highlight
the potential complexity of biologic therapy in a heterogeneous disease such as
SLE. Normal B cell numbers do not appear necessary for progression of some
cutaneous LE. The exacerbation of other lesions may indicate unwanted inhibition
of regulatory B cell function, or disruption of cytokine networks. 1. Vital EM et al.
Arthritis Rheum 2011 Oct;63(10):3038-47.
Cutaneous Manifestations Associated with Systemic Lupus Erythematosus
Disease Activity
L Sowerby1, E O’Brien1, L Joseph2, S Bernatsky2, 3, E Nashi4, E´ Vinet2,3, AE
Clarke2,4, CA Pineau3 1 Division of Dermatology, 2 Division of Clinical
Epidemiology, 3 Division of Rheumatology and 4 Division of Allergy and Clinical
Immunology, McGill University Health Centre, Montreal, Canada
This study examined the correlation of cutaneous manifestations with Systemic
Lupus Erythematous (SLE) and disease activity using the SLE Disease Activity Index
2000 (SLEDAI-2 K. Patients were recruited from a multispecialty SLE clinic. SLE
disease activity was assessed using the SLEDAI-2K which was modified by
eliminating muco-cutaneous items. Multiple linear regression models estimated the
effects of cutaneous manifestations on the SLEDAI-2K while adjusting for
confounding variables. Eighty subjects were recruited, of which 75 (93.8%) were
women. The mean SLEDAI-2K was 5.85 (SD 5.64). Of these patients, 24 (30%) had
one or more lupus-specific cutaneous manifestations. No association could be
demonstrated between the presence of lupus-specific skin findings and modified
SLEDAI-2 K scores. Lupus-non-specific cutaneous manifestations were found in 59
patients (73.8%), of which periungual telangiectasias (37 patients, 46.3%),
Raynaud’s (34, 42.5%) and livedo reticularis (27, 33.8%) were most frequent.
The presence of any lupus-non-specific finding is associated with a higher modified
SLEDAI-2 K. L. Lupus-non-specific cutaneous findings, particularly livedo reticu-
laris and periungual telangiectasias, are associated with increased SLE disease
activity. No association was demonstrated between lupus-specific cutaneous
manifestations and SLEDAI-2K. EThe presence of lupus-non-specific manifestations
may correlate with global disease activity.
Autoantibodies and disease activity in discoid lupus erythematosus patients
Kim A1, O’Brien J1, Song E1, Tseng L1, Zhang S2, Chong BF1 1 Department of
Dermatology, 2 Department of Clinical Science, University of Texas Southwestern
Medical Center, Dallas, USA
Identifying autoantibody biomarkers in discoid lupus erythematosus (DLE) could
help forecast disease progression and guide treatment. We sought to compare the
association of autoantibodies against nuclear antigens with disease activity markers
in DLE patients. Methods: A cross-sectional study was conducted on 95 DLE
patients in the University of Texas Southwestern Cutaneous Lupus Registry. ANA,
anti-dsDNA, anti-ssDNA, anti-RNP and additional anti-ENA autoantibodies were
measured on patient sera using ELISAs or multiplex bead array assays, and
compared to various disease activity markers. Results: In all DLE patients, ANA,
anti-RNP, and anti-dsDNA IgG correlated significantly with CLASI activity
(r¼0.21, P¼0.04 [ANA], r¼0.32, P¼0.002 [anti-RNP], r¼ 0.24, P¼0.02 [anti-
dsDNA]), SLEDAI scores (r¼0.37, Po0.001 [ANA], r¼0.34, Po0.001 [anti-RNP],
r¼ 0.35, Po0.001 [anti-dsDNA]), number of SLE criteria (r¼ 0.60, Po0.001
[ANA], r¼ 0.40, Po0.001 [anti-RNP], r¼ 0.49, Po0.001 [anti-dsDNA]), number
of oral lupus medications (r¼0.36, Po0.001 [ANA], r¼ 0.30, P¼ 0.003 [anti-
RNP], r¼0.37, Po0.001 [anti-dsDNA]), C3 levels (r¼0.52, Po0.001 [ANA],
r¼0.48, P¼ 0.002 [anti-RNP], r¼0.47, P¼0.003 [anti-dsDNA]), and C4 levels
(r¼0.47, P¼0.002 [ANA], r¼0.62, Po0.001 [anti-RNP], and r¼0.54,
Po0.001 [anti-dsDNA]). Similarly significant trends were seen in DLE patients with
positive ANAs (N¼77) and DLE pcatients with SLE (N¼ 46).: ANAs, anti-RNP, and
anti-dsDNA IgG correlate with measures of cutaneous and systemic disease activity
in DLE patients and may contribute to progression from cutaneous to systemic
disease.
Differential expression of BAFF and its receptors in discoid lupus erythematosus
subjects
Chong BF1, Tseng L1, Hosler GA1,2, Miller RT2, Kim A1, Yancey KB1 1 Department
of Dermatology, University of Texas Southwestern Medical Center, Dallas, USA
2 ProPath, Dallas, USA
Background: B-cell activating factor of the TNF family (BAFF) promotes B cell
maturation and survival. While BAFF levels are elevated in systemic lupus
erythematosus (SLE) patients, levels of BAFF and its receptors in discoid lupus
erythematosus (DLE) patients are unknown. Thus, we compared skin and blood
mRNA and protein levels of BAFF and its receptors BAFF-R, TACI, and BCMA in
DLEþ /SLEþ (N¼28), DLEþ /SLE- (N¼ 35), psoriasis (N¼11), and normal
(N¼ 42) subjects. Methods: We used quantitative real-time PCR to measure blood
and skin BAFF, BAFF-R, TACI, and BCMA mRNA, sandwich ELISAs to measure sera
BAFF, and immunohistochemistry to evaluate BAFF and BAFF-R skin protein
expression. Results: BAFF mRNA and protein levels were highest in DLEþ /SLEþ
blood, followed by DLEþ /SLE-, psoriasis, and normal blood. While showing no
difference between DLEþ /SLEþ and DLEþ /SLE- skin, BAFF and its receptors
mRNA were up-regulated in DLE skin versus normal and psoriasis skin. DLE skin
had higher percentages of BAFF-Rþ inflammatory cells, likely T cells and
macrophages, than psoriasis and normal skin. Conclusions: BAFF may serve as a
serologic marker of systemic disease in DLE patients. BAFF and its receptors are
elevated in DLE skin, suggesting that targeted therapies against these proteins could
treat refractory DLE patients.
Lupus Profundus-Induced Facial Atrophy: Safe and Effective Treatment with
Poly-L-Lactic Acid and Hyaluronic Acid Dermal Fillers
AB Eastham1,2 and CA Liang 2, AN Femia2, TC Lee3, RA Vleugels2, JF Merola MD24
1 Harvard Combined Dermatology Residency Program, 2 Department of
Dermatology, 3 of Radiology, and 4 of Medicine, Division of Rheumatology,
Allergy, and Immunology, Brigham and Women’s Hospital and Harvard Medical
School; Boston, USA
Lupus erythematosus panniculitis (LEP), an inflammatory disease of the subcuta-
neous tissue, often resolves with permanent atrophy, for which there are few
effective treatments. We present a 30-year-old woman with prominent LEP-induced
malar atrophy, diagnosed 9 years prior without evidence of systemic lupus. She
denied disease activity for several years while on chloroquine, dapsone, and
photoprotection. She desired minimally-invasive correction of her facial disfigure-
ment. MRI was performed to exclude subclinical disease, which showed no
underlying inflammation. While continuing medical therapy, a vial of poly-L-lactic
acid (PLLA) (Sculptras, 1:8 dilution) was injected along the malar eminences..
Repeat injections were performed 4 weeks later. After 5 months, modest
improvement was evident. For further volume enhancement, 2 cc of hyaluronic
acid (HA) (Juve´derm Ultra Pluss) were injected into lesional dermis. The patient
reported high satisfaction. No nodules, skin or systemic disease reactivation
occurred after 11 months. We present the first case of LEP-induced facial atrophy
successfully treated with PLLA and HA. These agents should be considered
therapeutic options for correction of LEP-induced facial atrophy in the context of
quiescent LEP. Furthermore, MRI may be helpful to exclude subclinical disease.
Systemic involvement in TREX1-associated familial chilblain lupus
C Gu¨nther1, M Hillebrand3, J Brunk3, MA Lee-Kirsch2, MD 1 Department of
Dermatology, 2 Department of Pediatirics, University Hospital, Technical
University Dresden, Dresden, Germany, 3 Department of Rheumatology, Clinical
Immunology and Physical Therapy, Katholisches Klinikum Mainz, Standort St.
Vincenz und Elisabeth Hospital, Mainz, Germany
Familial chilblain lupus is a rare monogenic form of cutaneous lupus caused by
heterozygous mutation of TREX1 (30repair exonuclease). Here we describe the
unusual case of a patient from a family with TREX1-associated chilblain lupus who
developed typical acral chilblain lesions in early childhood and during
adolescence presented with a progressive disease course with hematologic
involvement, polyarthritis and antinuclear antibodies. This suggests that the clinical
picture of familial chilblain lupus is not restricted to cutaneous involvement but
may also include systemic manifestations.
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DERMATOMYOSITIS BASIC SCIENCE
Amyopathic Dermatomyositis and Its Classification
RD Sontheimer Department of Dermatology, University of Utah School of
Medicine, Salt Lake City, USA
The dermatologic conceptualization of ‘‘amyopathic dermatomyositis’’ (ADM) was
initially published in 1991 as a small case series. Prior to that, the idea that the
hallmark cutaneous manifestations of human dermatomyositis (DM) could exist for
unusually extended periods of time (6 months or longer) without accompanying
clinically-significant muscle and/or lung inflammation had not been formally
studied other than through anecdotal comments under the designation of
‘‘dermatomyositis sine myositis’’ (DSM). Over the past two decades the published
record of ADM has grown substantially (296 PubMed citations as of March 17,
2013). During this timeframe a few additional studies in this area have been
reported under the designation ‘‘DSM’’ by traditionalists who have been reticent to
accept the ADM concept. While most of the currently available published data on
ADM are from anecdotal and observational studies, some population-based data
does now exist. In this presentation, the current body of available evidence
concerning ADM/DSM will be reviewed from the perspective of an interested
clinician caring for such patients. The clinical concept of ADM/DSM hinges
critically on the physician’s ability to confidently distinguish the cutaneous
manifestations of DM from those of cutaneous LE and other potentially confounding
inflammatory dermatoses. However, the minimal set of cutaneous findings
(clinical, histopathologic, immunologic) necessary to establish a diagnosis of
cutaneous DM have to date yet to be universally agreed upon.
Lung diseases in dermatomyositis
Ang Chia Chun Philadelphia Veterans’ Affairs Medical Center and Department of
Dermatology, University of Pennsylvania, Philadelphia USA; Department of
Dermatology, Changi General Hospital, Singapore
Lung complications can be seen in up to 46% of patients with idiopathic
inflammatory myopathies (IIM) and contributes to the mobidity and mortality. The
lung parenchyma, pulmonary vessels or respiratory muscles can be affected.
Interstitial lung disease (ILD) has a prevalence of 5% to 65%. It has a variable onset
and can be asymptomatic, chronic, acute or fulminant in its course. The
pathogenesis of ILD in IIM is hypothesised to be a cross-reacting immune response
against specific antigenic targets expressed in injured myocytes and the lung.
Patients with anti-MDA5, anti-synthethase and anti-PM-Scl antibody defined
disease subtypes are at the highest risk of developing ILD, but caveats such as
differing sensitivity and specificity and availability of such antibody testing limits its
use. We propose that all DM patients be screened with a pulmonary function test
(PFT), followed by a high resolution chest computer tomography as well as a
pulmonary consult should the PFT be abnormal. In the absence of significant
abnormalities, the PFT can be repeated yearly. The management of ILD requires a
multidisciplinary approach involving the pulmonologist, dermatologist, rheumatol-
ogist and radiologist. There are no controlled studies for the treatment of ILD in IIM,
but different immunosuppressive agents have been used. Aspiration pneumonia
and hypoventilation can affect patients with active myositis, while pneumothorax,
pulmonary hypertension and drug induced pulmonary fibrosis are uncommon.
Autoantibody-based classification of dermatomyositis
M Fujimoto Department of Dermatology, Kanazawa University, Kanazawa Japan
Dermatomyositis (DM) is a heterogeneous group of disorders with varying degrees
of muscle disease, cutaneous manifestations, and internal organ involvement.
Myositis-specific autoantibodies (MSAs) are useful tools since they further define
more homogeneous subsets. Earlier studies have established that anti-aminoacyl
tRNA synthetase antibodies identify patients who share similar clinical features
including interstitial lung disease and myositis, which are referred to as ‘‘anti-
synthetase syndrome’’, and that anti-Mi-2 antibody represents a distinct DM
phenotype with benign clinincal course. Recently, autoantibodies to melanoma
differentiation antigen 5 (MDA5) and transcriptional intermediary factor 1 (TIF1)
have been described. Anti-MDA5 antibody has been considered as serological
markers for clinically amyopathic DM with rapidly progressive interstitial lung
disease frequently found in Asia. Anti-TIF1 antibody is predominantly detected in
those with juvenile DM and adult cancer-associated DM. Furthermore, studies have
revealed that anti-MJ (NXP-2) and anti-small ubiquitin-like modifier activating
enzyme (SAE) autoantibodies also form clinically distinct subsets. Identification of
the autoantibody profile in an individual DM patient is beneficial for management
and therapy.
Murine models of autoimmune myositis
N Okiyama123, T Sugihara1, H Yokozeki2, H Kohsaka1 1 Department of Medicine
and Rheumatology, 2 Department of Dermatology, Tokyo Medical and Dental
University, Tokyo, Japan, and 3 Dermatology Branch, CCR, NCI, NIH, Bethesda,
USA
According to a classical view in polymyositis (PM) and dermatomyositis (DM). It is
currently suggested that T cell-mediated cytotoxicity dominate in the muscle injury.
We established a new murine model of autoimmune myositis, C protein-induced
myositis (CIM) of B6 mice immunized with human or murine skeletal muscle C
protein fragments (Sugihara et al. Arthritis Rheum 2007, Okiyama et al. Arthritis
Rheum 2009). CD8T cells directly injure muscle fibers in CIM (Sugihara et al.
Arthritis Rheum 2010). We identified an epitope with high affinity to MHC I in the
C protein fragment. Transfer of bone marrow-derived dendritic cells (BMDCs)
presenting this peptide induced CD8T cell-mediated myositis (un-published data).
This model demonstrates that autoaggressive CD8T cells can induce muscle injury.
In CIM, blockage of IL-1, TNFa or IL-6 was effective treatment (Okiyama et al.
Arthritis Rheum 2009, Sugihara et al. Arthritis Rheum 2012). Interestingly, adoptive
transfer of T cells from CIM mice induced myositis exclusively in legs treated with
adjuvants. It shows that development of CIM requires both autoaggressive T cells
and conditioning of the muscle tissues, inspiring us to propose ‘seed and soil’
(Okiyama et al. Arthritis Rheum 2012). The ‘seed and soil’ model seems useful in
understanding clinical aspects of PM/DM.
Treatment of dermatomyositis
B Volc-Platzer
Objective: Overview of current standard potential new therapies, based on
advances in understanding the pathogenesis of inflammatory myopathies and
disease subsets. Recent findings: Standard induction treatment of dermatomyositis
is based on systemic corticosteroids, 0.5 –2.0mg/kg bw/day until control of muscle
disease, followed by slow tapering. About 90% of patients improve within 2 – 3
years and remain free of disease. To avoid long-term corticosteroid effects, other
immunosuppressants such as methotrexate, azathioprine or mycophenolate mofetil
are added to corticosteroids and/or used as second line treatments. Despite the lack
of randomized controlled trials with the standard immunosuppressive and/or
immunomodulatory agents there is general expert consensus about their use in
dermatomyositis. Second line treatment includes high dose intravenous immuno-
globulins which has been confirmed in one controlled, randomized, double-blind
and cross-over trial. Evidence for other immunosuppressive therapies is derived
from uncontrolled studies or case series. Systemic calcineurin inhibitors are
effective in interstitial lung disease and anti-synthetase autoantibodies. Whether
patients with dermatomyositis benefit from the use of rituximab, eculizumab or
TNF-alpha inhibitors requires further randomized clinical trials. Tocilizumab and
ACTH analogues also require controlled studies, as well as pharmacoeconomic
evaluation. Summary: Traditional immunosuppressive and immunomodulatory
treatments are successful in about 90% of patients. With the advancing
understanding of the pathogenesis of inflammatory myopathies including derma-
tomyositis as well as ongoing improvement in defining patients’ profiles, standard
as well as newer therapies may be used more targeted and thus more beneficial for
individual patients.
DERMATOMYOSITIS CLINICAL
Characteristics of cancer-associated dermatomyositis
M Hasegawa Department of Dermatology, Faculty of Medicine, Institute of
Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa,
Japan
Clinical manifestations of Dermatomyositis (DM) are heterogeneous, with varying
degrees of skin rash, myositis, and accompanying symptoms such as interstitial lung
disease and internal malignancy. The association of malignancy with DM, which is
termed cancer-associated DM, is well known. The reported incidence of associated
malignancy in adult DM varies from 10B40%. Since malignant disease is one of
the main causes of mortality in these patients, diagnosing occult cancer in them is
critical. Patients with DM frequently have autoantibodies that target nuclear and/or
cytoplasmic antigens. Interestingly, these autoantibodies are highly specific and are
closely associated with specific clinical phenotypes within the disease. Therefore,
these myositis-specific autoantibodies are useful tools to define more homogeneous
clinical subsets in DM. Among them, recent studies demonstrated that auto-
antibodies called as anti-p155 antibodies or anti-155/140 antibodies are correlated
with cancer-associated DM. These autoantibodies target transcription intermediary
factor 1 (TIF-1) family protein that has significant roles in oncogenesis. The
association of anti-TIF-1 antibodies with cancer has been described in a number of
reports concerning adult DM. It is also noteworthy that anti–TIF-1 antibodies are
detected in young adult DM and juvenile DM without malignancy. In our Japanese
cohort, 65% of adult patients with the antibodies had cancer. Our patients with
anti-TIF1 antibodies developed heliotrope rash, Gottron’s papules or sign and
flagellate erythema significantly more frequently than patients without the
antibodies.
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Seborrheic area erythema as a common skin manifestation in Japanese patients
with dermatomyositis.
N Okiyama12, H Kohsaka2, I Katayama3, H Yokozeki1 1 Department of
Dermatology, 2 Department of Medicine and Rheumatology, Tokyo Medical and
Dental University, Tokyo, Japan, and 3 Department of Dermatology, Osaka
University, Osaka, Japan
Patients with dermatomyositis (DM) present various skin manifestations, of which
pathogenesis remains poorly understood. Although facial erythema was noted in
the nasolabial folds of Japanese DM patients in the past study, other DM-associated
facial macular violaceous erythema (MVE) than heliotrope rash has drawn little
attention in previous studies. To characterize phenotypical features and frequencies
of DM-associated MVE, we performed a retrospective study on skin manifestations
in 33 Japanese DM patients. We found that facial MVE was most frequent in our
series (67 %). Patients with facial MVEs had also MVEs in the scalp significantly
more frequently (36 %) than those without facial MVEs (0 %). Because the facial
and scalp MVEs have a distribution similar to seborrheic dermatitis (SD), we termed
the skin manifestations seborrheic area erythemas (SAEs). In addition, histological
findings of SAEs disclosed that all specimens with prominent DM-associated
changes including liquefaction degeneration of the basal cell layer were
accompanied by changes compatible with SD, such as parakeratosis of the corneal
layer and sparse neutrophil infiltration in the epidermis. The findings indicated a
triggering SAE by SD, which is known as Ko¨bner phenomenon.
Determination of cutaneous dermatomyositis severity using the cutaneous
dermatomyositis disease area and severity index
C Anyanwu,1,2 K Propert,3 VP Werth1,2 1 Veterans Affairs Medical Center, 2
Department of Dermatology and 3 Department of Biostatistics and Epidemiology,
University of Pennsylvania; Philadelphia, PA
Development of novel therapies for dermatomyositis (DM) necessitates outcome
measures that reliably assess disease progression and treatment efficacy. The
Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) was
developed to systematically assess DM severity. We aim to classify DM severity
using CDASI activity scores of adult patients in a cross-sectional study. Patient
information was collected using questionnaires completed during office visits.
Ninety-one patients were included in the analysis. Subjects were representative of
DM including 52% with classic DM, 43% with amyopathic DM and 5% with
hypomyopathic DM. The principal investigator, using the CDASI and a PGA Likert
scale, scored disease activity at each encounter. On the Likert scale, 65% of
patients had none or mild disease, 31% had moderate disease and 4% had severe
disease. The median CDASI scores for mild, moderate and severe disease were 13,
27 and 35 respectively. CDASI scores increased with disease severity, confirming
the construct validity of this instrument. A receiver-operating characteristic curve
generated via logistic regression indicates that cut-off of approximately 20 out of
100 points on the CDASI best distinguishes subjects with none-mild disease from
those with moderate-severe disease (sensitivity 88%; specificity 86%, area under
the ROC curve 92%). This study contributes to continued efforts to validate the
CDASI.
Dermatomyositis patients with mechanic’s hands have a higher risk of both early
and established interstitial lung disease
CC Ang, C Anyanwu, and VP Werth Philadelphia VA Medical Center and the
Department of Dermatology, University of Pennsylvania
We performed a chart analysis to examine the relationship between selected
clinical signs (mechanic’s hands, skin ulcers, oral ulcers, gottron’s papules,
alopecia and arthritis/arthralgia) and ILD in a prospective cohort of patients with
adult onset DM enrolled in the Penn dermatomyositis database from 2008 to 2012.
Patients underwent yearly pulmonary function tests (PFT) and had high resolution
chest computer tomography (HRCT) performed if PFT cowas abnormal. Patients
with either early ILD (an isolated low [o80% predicted] lung diffusion capacity) or
HRCT-confirmed ILD were analysed as an outcome group. Of the 89 patients
analysed. 56.2% had classical DM, 43.8% had clinically amyopathic DM, 85.4%
were female and 93.3% were Caucasians. The median duration of disease was 5.1
years and the median duration of follow-up was 2.9 years. Twenty eight patients
had early ILD or HRCT-confirmed ILD while 61 patients did not have ILD. No
differences were seen for the type of DM, CDASI activity scores, gender, race,
smoking status, treatment status, age and duration of disease. Only mechanic’s
hands conferred a relative risk of 2.56 of having either early ILD or HRCT-
confirmed ILD in all DM patients (95% confidence interval¼1.21 to 5.41,
P¼ 0.01). Patients with DM should undergo regular yearly screening PFT,
especially in those with mechanic’s hands.
SCLERODERMA BASIC SCIENCE
The possible mechanisms of ultraviolet A1 irradiation in the improvement of
bleomycin-induced scleroderma.
T Ikeda, N Kanazawa, F Furukawa Department of Dermatology, Wakayama
Medical University, Wakayama, Japan
Ultraviolet A1 (UVA1) phototherapy is successfully used for the treatment for
various skin diseases including the sclerotic skin diseases. UVA1 irradiation
induces infiltrating T cell apoptosis in atopic dermatitis and psoriasis. However
there are few reports about the relation between the improvement of the skin
sclerosis and the effect to induce pathogenic infiltrating cell apoptosis. In murine
model of bleomycin-induced scleroderma, dermal sclerosis was reported to be
associated with apoptosis of infiltrating mononuclear cells. We examined
irradiation of UVA1 (10 or 40 J/cm2 per time, 5 times per week, for 2 weeks) to
bleomycin-induced scleroderma model mice and to estimate the correlation
between the changes of apoptosis and the improvement of skin sclerosis.
Histological dermal thickness was thinner and density of dermal TUNEL positive
cells decreased more in mice irradiated UVA1 than those in mice administrated
without irradiation significantly. The density of dermal TGFb positive cells did not
change, but the density of dermal TGFb receptor type II positive cells decreased
more. The decrease of the expression of TGFb receptor type II in dermal cells may
influence the collagen production. UVA1 irradiation may have the distinct effect
about apoptosis for dermal cells, though UVA1 have the effect to induce
pathogenic infiltrating skin cell apoptosis in atopic dermatitis and psoriasis.
OTHER
Thomas T. Provost, M.D. – A Memorial
RD Sontheimer Department of Dermatology, University of Utah School of
Medicine, Salt Lake City, USA
Dr Thomas T. Provost died on April 18, 2012 in Baltimore, Maryland, USA from
complications of colon cancer. Tom Provost was one of the most visible leaders if
USA rheumatologic dermatology in the 1960s–1990s. In collaborative studies with
Dr Morris Reichlin Dr Provost helped pioneer the serologic sub-setting of
autoimmune connective tissue diseases, especially systemic lupus erythematosus
(SLE) and Sjogren’s syndrome. Tom’s earlier research also help clarify the clinical
phenomena of ‘‘antinuclear antibody-negative’’ SLE, subacute cutaneous LE and
neonatal LE. His team later characterized the diverse central nervous system
manifestations of Sjogren’s syndrome. Dr Provost co-edited the only textbook
published to date that has been devoted exclusively to the cutaneous manifestations
of rheumatic diseases. He was a leader in American Dermatology as highlighted by
his service as Chairman of the Department of Dermatology at Johns Hopkins
University and election to membership in the American Dermatology Association.
Tom was a recipient of the American Academy of Dermatology’s Marion
Sulzberger Award and the inaugural recipient of Medical Dermatology Society’s
Lifetime Achievement Award (Tom was one of the three Founders of the Medical
Dermatology Society in the 1990s). However, Tom’s friends and colleagues will
remember him equally from his warm personal traits: his always-smiling face, his
sociable personality, his collaborative nature and his very strong regard for the
welfare of the younger people around him.
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